IP Lignocaine bolus and infusion — Competitive Intelligence Brief

IP Lignocaine bolus and infusion (IP Lignocaine bolus and infusion) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic / Antiarrhythmic agent. Area: Anesthesia / Cardiology.

marketed Local anesthetic / Antiarrhythmic agent Voltage-gated sodium channels Anesthesia / Cardiology Small molecule

Target snapshot

IP Lignocaine bolus and infusion (IP Lignocaine bolus and infusion) — University of Auckland, New Zealand. Lignocaine (lidocaine) is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IP Lignocaine bolus and infusion TARGET	IP Lignocaine bolus and infusion	University of Auckland, New Zealand	marketed	Local anesthetic / Antiarrhythmic agent	Voltage-gated sodium channels
Exparel/bupivacaine mixture	Exparel/bupivacaine mixture	Wake Forest University Health Sciences	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Bupivacaine Liposomes(BL)	Bupivacaine Liposomes(BL)	Huazhong University of Science and Technology	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Lidocaine + Prilocaine	Lidocaine + Prilocaine	Galeno Desenvolvimento de Pesquisas Clínicas	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Hyperbaric bupivacaine+Morphine	Hyperbaric bupivacaine+Morphine	Fundación Pública Andaluza Progreso y Salud	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptors (morphine)
ESL	ESL	Bial - Portela C S.A.	marketed	Voltage-gated sodium channel blocker; anticonvulsant	Voltage-gated sodium channels (Nav)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic / Antiarrhythmic agent class)

1. University of Auckland, New Zealand · 1 drug in this class